Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Jan
3
2023
FDA Releases 2022 Edition of the Food Code Keller and Heckman LLP
Jan
3
2023
A Way Too Early Prediction: Alabama Cannabis 2.0 Bradley Arant Boult Cummings LLP
Dec
31
2022
China to Remove Infringing Pharmaceuticals from Procurement Platforms Schwegman, Lundberg & Woessner, P.A.
Dec
30
2022
Potential Litigation Impacts of the Modernization of Cosmetics Regulation Act of 2022 Greenberg Traurig, LLP
Dec
30
2022
Companies Gear Up For Mass Production of Cultured Meat Womble Bond Dickinson (US) LLP
Dec
30
2022
New Cosmetic Regulatory Requirements: What Cosmetic Manufacturers Need to Know Greenberg Traurig, LLP
Dec
29
2022
Mississippi Medical Cannabis, Charles Dickens Style Bradley Arant Boult Cummings LLP
Dec
29
2022
Welcome (but Last Minute) Relief for Prescription Drug Reporting Originally Due December 27 McDermott Will & Emery
Dec
29
2022
Petition Filed to Add Polyoxymethylene to List of Chemical Substances Subject to Superfund Excise Tax Bergeson & Campbell, P.C.
Dec
29
2022
Doctor-Patient Relationships and Medical Marijuana: Where Are We Now?
Dec
28
2022
EPA Finds Carbon Tetrachloride, as a Whole Chemical Substance, Poses an Unreasonable Risk to Human Health Bergeson & Campbell, P.C.
Dec
28
2022
Consolidated Appropriations Act, 2023 Contains Significant Provisions for Cosmetic Products ArentFox Schiff LLP
Dec
28
2022
RxDC Reporting Relief for Plans, Issuers, and Plan Service Providers Foley & Lardner LLP
Dec
28
2022
Federal Regulators Offer Employer Health Plans Last-Minute Relief on Prescription Drug Reporting Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Dec
27
2022
EPA Announces Removal of PFAS Chemicals from Approved Inert Ingredient List for Pesticide Products Bergeson & Campbell, P.C.
Dec
27
2022
FDA Expands Inspection Guidance to Apply to Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Dec
24
2022
Back to the Drawing Board: CMS Proposes Changing the Overpayment Rule’s “Identified” Definition McDermott Will & Emery
Dec
24
2022
The Greatest Gift of All…Tri-Agencies Issue Welcome Relief on Prescription Drug Reporting Proskauer Rose LLP
Dec
23
2022
OECD Accepting Comment on Draft Study Report on Applicability of the key event based TG 442D for in vitro skin sensitisation testing of nano-materials Bergeson & Campbell, P.C.
Dec
22
2022
Omnibus Bill for Fiscal Year 2023 (H.R. 2617) – Cosmetics Summary Keller and Heckman LLP
Dec
22
2022
Consumer Reports Evaluates Heavy Metals in Chocolate Keller and Heckman LLP
Dec
22
2022
Heinz PFAS Consumer Fraud Lawsuit Continues 2022 Trend CMBG3 Law
Dec
21
2022
PTO Expands the Scope of the Immunotherapy Pilot Program
Dec
21
2022
ANSES Applies Methodology to Assess Risks of Nanomaterials in Food to Titanium Dioxide Bergeson & Campbell, P.C.
Dec
21
2022
FTC Revises Longstanding “Dietary Supplement Guide” to Cover all Health Products Hunton Andrews Kurth
Dec
21
2022
FDA Issues Final Guidance on GRAS Panel Best Practices Keller and Heckman LLP
Dec
20
2022
Comment Period for “Healthy” Regulations Extended; But Consumer Class Actions Targeting “Health Halos” May Continue Sheppard, Mullin, Richter & Hampton LLP
Dec
20
2022
OSTP Publishes RFIs on Coordinated Framework for the Regulation of Biotechnology and National Biotechnology and Biomanufacturing Initiative Bergeson & Campbell, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins